Determining the sensitivity of primary acute myeloid leukemia (AML) samples with FLT3-ITD or FLT3-D835 mutations to FLT3 inhibitors using an ex vivo drug sensitivity screen

Authors :: Cristina E. Tognon
Brian J. Druker
Jeffrey W. Tyner
Kevin Watanabe-Smith
Mara Rosenberg
Guang Fan
Marc M. Loriaux
Source :: Journal of Clinical Oncology. 36:7025-7025
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: 7025Background: AML has high molecular complexity and certain markers are predictors of overall survival. Mutations in FLT3-ITD, for example, lead to a poor prognosis with outcomes further worsened...

Subjects :: Molecular complexity
Drug
Cancer Research
Poor prognosis
business.industry
media_common.quotation_subject
Myeloid leukemia
Oncology
hemic and lymphatic diseases
Cancer research
Overall survival
Medicine
business
Ex vivo
media_common
Flt3 itd

Full Text Access

Tools